Decreased susceptibility to copper-induced oxidation of rat-lipoproteins after fibrate treatment: influence of fatty acid composition
- PMID: 8882610
- PMCID: PMC1909812
- DOI: 10.1111/j.1476-5381.1996.tb16710.x
Decreased susceptibility to copper-induced oxidation of rat-lipoproteins after fibrate treatment: influence of fatty acid composition
Abstract
1. The effect of clofibrate (CFB), bezafibrate (BFB), and gemfibrozil (GFB) on plasma lipoprotein (VLDL and LDL) concentration, composition and resistance to copper-induced oxidation has been studied in male Sprague-Dawley rats after a 15 day treatment. 2. Plasma triglyceride levels were reduced by CFB (41%) and BFB (39%). This effect was related to a significant reduction (67% for CFB and 56% for BFB) in the amount of circulating VLDL-protein. 3. Plasma total cholesterol was reduced by 28% and 45% in CFB- and BFB-treated animals, respectively, mainly by modification of the cholesteryl ester fraction. In contrast, GFB significantly increased total cholesterol (27%). No modification in the LDL protein or lipid content was introduced by fibrates, although GFB decreased the proportion of LDL-triglycerides, at the expense of an increase in total cholesterol. 4. The fatty acid species carried by VLDL and LDL were affected after fibrate treatment. In general, both particles showed an increase in monounsaturated fatty acids (MUFA) (18:1) and a decrease in polyunsaturated fatty acids (PUFA) species (18:2 n-6, 20:4 n-6, 18:3 n-3, 20:5 n-3). As a consequence, the ratio of PUFA/(SFA+MUFA) for the whole lipoproteins was markedly reduced. 5. The degree of copper-induced VLDL- and LDL-oxidation was assessed by means of the analysis of lysine content, thiobarbituric acid reactive substances (TBARS) production and conjugated dienes formation. Lipoproteins obtained from fibrate-treated rats were more resistant to the oxidative challenge. For each lipoprotein, BFB was the most effective drug, followed by CFB and GFB. 6. The observed antioxidant effect can be ascribed to two independent phenomena produced by fibrates: the reduction of the amount of substrate for the oxidation process due to their hypolipidemic activity, and the alteration in the type of fatty acids transported by the lipoproteins towards an enrichment in species resistant to the oxidation process. 7. As similar lipoprotein fatty acid changes have been reported after fibrate treatment in human subjects, an antioxidant effect of fibrates in human therapy, independent of their well known hypolipidaemic activity, should be expected.
Similar articles
-
Selective modification of rat hepatic microsomal fatty acid chain elongation and desaturation by fibrates: relationship with peroxisome proliferation.Br J Pharmacol. 1995 Apr;114(7):1351-8. doi: 10.1111/j.1476-5381.1995.tb13355.x. Br J Pharmacol. 1995. PMID: 7606338 Free PMC article.
-
Different effects of fibrates on the microsomal fatty acid chain elongation and the acyl composition of phospholipids in guinea-pigs.Br J Pharmacol. 1995 Dec;116(8):3337-43. doi: 10.1111/j.1476-5381.1995.tb15144.x. Br J Pharmacol. 1995. PMID: 8719816 Free PMC article.
-
Differential effects of fibrates on the acyl composition of microsomal phospholipids in rats.Br J Pharmacol. 1995 Oct;116(3):2067-75. doi: 10.1111/j.1476-5381.1995.tb16413.x. Br J Pharmacol. 1995. PMID: 8640347 Free PMC article.
-
Fibric acids: effects on lipids and lipoprotein metabolism.Am J Med. 1987 Nov 27;83(5B):9-20. doi: 10.1016/0002-9343(87)90866-7. Am J Med. 1987. PMID: 3318457 Review.
-
Mechanism of action of fibrates on lipid and lipoprotein metabolism.Circulation. 1998 Nov 10;98(19):2088-93. doi: 10.1161/01.cir.98.19.2088. Circulation. 1998. PMID: 9808609 Review.
Cited by
-
Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases.Mediators Inflamm. 2013;2013:549627. doi: 10.1155/2013/549627. Epub 2013 May 27. Mediators Inflamm. 2013. PMID: 23781121 Free PMC article. Review.
-
Lipoprotein composition and oxidative modification during therapy with gemfibrozil and lovastatin in patients with combined hyperlipidaemia.Br J Clin Pharmacol. 1998 Mar;45(3):265-9. doi: 10.1046/j.1365-2125.1998.00672.x. Br J Clin Pharmacol. 1998. PMID: 9517370 Free PMC article. Clinical Trial.
-
Bezafibrate induces acyl-CoA oxidase mRNA levels and fatty acid peroxisomal beta-oxidation in rat white adipose tissue.Mol Cell Biochem. 2001 Jan;216(1-2):71-8. doi: 10.1023/a:1011060615234. Mol Cell Biochem. 2001. PMID: 11216866
-
Activation of Peroxisome Proliferator-Activated Receptor-α Increases the Expression of Nuclear Receptor Related 1 Protein (Nurr1) in Dopaminergic Neurons.Mol Neurobiol. 2019 Nov;56(11):7872-7887. doi: 10.1007/s12035-019-01649-y. Epub 2019 May 24. Mol Neurobiol. 2019. PMID: 31127527 Free PMC article.
-
The Effects of Long-Term Dietary Therapy on Patients with Hypertriglyceridemia.J Atheroscler Thromb. 2019 Jan 1;26(1):39-49. doi: 10.5551/jat.42440. Epub 2018 May 22. J Atheroscler Thromb. 2019. PMID: 29794409 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous